Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor

Novartis appears to be throwing in the towel on its Xolair-successor hopeful. The Swiss pharma’s Phase III peanut allergy trial for ligelizumab has been terminated, according to a ClinicalTrials.gov update Tuesday.